Myriad Genetics (NASDAQ:MYGN) announced it has appointed Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. Mr. Donnelly brings more than 20 years of leadership experience in healthcare...
Tag - MYGN
Copyright © 2025 BioTuesday Publishing Corporation - Privacy Policy